NCT06622694
CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Stopped Recruitment suspended Sponsor's reason: Suboptimal treatment response
- Eligibility criteria expanded, about 33 words
- Study completion pushed from Dec 31, 2026 to Oct 31, 2027
- Site details revised
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Oct 7, 2024 to Jun 19, 2025
- Site details revised
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
Endpoints
Primary
Secondary (1)
Arms and interventions
RD13-02 is a genetically engineered T cell product derived from healthy donors, designed to express a chimeric antigen receptor (CAR) targeting CD7 on its cell membrane. This modification enables the CAR T cells to specifically kill CD7-positive tumor cells. CD7 is expressed on the surface of both normal and malignant T cells. The extracellular domain of RD13-02 consists of a humanized single-chain antibody targeting CD7, while the co-stimulatory domain is derived from TNFRSF9 (CD137 or 4-1BB). The CAR is cloned into a clinical-grade retroviral vector and introduced into human T cells via retroviral transduction. To prevent "fratricide," RD13-02 has had surface CD7 expression knocked out, and TCR knockout is implemented to prevent graft-versus-host disease (GvHD). HLA knockout and NK cell introduction further reduce the risk of rejection.
Biologicals: RD13-02
Sites
1 site in 1 country
- Regenerative Medicine Clinic CenterTianjin, Tianjin Municipality, China